dc.contributor.author | King, A | |
dc.contributor.author | Doepner, A | |
dc.contributor.author | Turton, D | |
dc.contributor.author | Ciobota, DM | |
dc.contributor.author | Da Pieve, C | |
dc.contributor.author | Wong Te Fong, A-C | |
dc.contributor.author | Kramer-Marek, G | |
dc.contributor.author | Chung, Y-L | |
dc.contributor.author | Smith, G | |
dc.date.accessioned | 2018-03-20T14:56:48Z | |
dc.date.issued | 2018-04-25 | |
dc.identifier.citation | Organic & biomolecular chemistry, 2018, 16 (16), pp. 2986 - 2996 | |
dc.identifier.issn | 1477-0520 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1603 | |
dc.identifier.eissn | 1477-0539 | |
dc.identifier.doi | 10.1039/c8ob00432c | |
dc.description.abstract | Trifluoromethyl groups are widespread in medicinal chemistry, yet there are limited 18F-radiochemistry techniques available for the production of the complementary PET agents. Herein, we report the first radiosynthesis of the anticancer nucleoside analogue trifluridine, using a fully automated, clinically-applicable 18F-trifluoromethylation procedure. [18F]Trifluridine was obtained after two synthetic steps in <2 hours. The isolated radiochemical yield was 3% ± 0.44 (n = 5), with a radiochemical purity >99%, and a molar activity of 0.4 GBq μmol-1 ± 0.05. Biodistribution and PET-imaging data using HCT116 tumour-bearing mice showed a 2.5 %ID g-1 tumour uptake of [18F]trifluridine at 60 minutes post-injection, with bone uptake becoming a prominent feature thereafter. In vivo metabolite analysis of selected tissues revealed the presence of the original radiolabelled nucleoside analogue, together with deglycosylated and phosphorylated [18F]trifluridine as the main metabolites. Our findings suggest a potential role for [18F]trifluridine as a PET radiotracer for elucidation of drug mechanism of action. | |
dc.format | Print | |
dc.format.extent | 2986 - 2996 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ROYAL SOC CHEMISTRY | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Radiosynthesis of the anticancer nucleoside analogue Trifluridine using an automated 18F-trifluoromethylation procedure. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-03-16 | |
rioxxterms.versionofrecord | 10.1039/c8ob00432c | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-04 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Organic & biomolecular chemistry | |
pubs.issue | 16 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/PET Radiochemistry | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/PET Radiochemistry | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics | |
pubs.publication-status | Published | |
pubs.volume | 16 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | PET Radiochemistry | |
icr.researchteam | Preclinical Molecular Imaging | |
icr.researchteam | Radioisotope Physics | |
dc.contributor.icrauthor | King, Alice | |
dc.contributor.icrauthor | Da Pieve, Chiara | |
dc.contributor.icrauthor | Kramer-Marek, Gabriela | |
dc.contributor.icrauthor | Chung, Yuen-Li | |
dc.contributor.icrauthor | Smith, Graham | |